Dual Trigger vs HCG Trigger for Final Maturation in Normal Responders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial compares two methods to trigger final oocyte maturation in normal-responder women undergoing ICSI with a GnRH antagonist protocol. Participants are randomized to receive either a dual trigger (GnRH agonist plus hCG) or an hCG trigger alone. Primary outcome is the number of mature MII oocytes, with secondary outcomes including total oocytes retrieved, fertilization rate, embryo quality, implantation rate, clinical pregnancy rate, multiple pregnancy rate, and OHSS incidence. Eligible participants are women aged 20-40 with BMI 18-30, normal ovarian reserve, and undergoing their first or second ICSI cycle. Exclusion criteria include poor or high ovarian response, PCOS, high Day-of-trigger E2, significant endocrine disorders, uterine abnormalities, or severe systemic disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women aged 20-40 years.
* Body mass index (BMI) between 18 and 30 kg/m².
* Undergoing ICSI treatment using a GnRH antagonist protocol.
* Normal ovarian reserve and expected normal ovarian response.
* AMH between 1.2 - 3.5 ng/ml
* AFC 7-15 follicle.
* First or second ICSI cycle.

Exclusion Criteria:

* Poor ovarian response (Bologna/POSEIDON criteria)
* High ovarian response with a risk of ovarian hyperstimulation syndrome (OHSS) AMH \> 3.5 ng/ml or AFC \> 15 follicle.
* Polycystic ovary syndrome (PCOS).
* Serum E2 level \> 3500 pg/ml at day of triggering.
* Endocrine disorders including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, or Cushing syndrome.
* Congenital uterine abnormalities.
* Severe systemic diseases affecting fertility outcomes.

Where it's running

• ART Unit, International Islamic Center for Population Studies and Research, Al-Azhar University
  Cairo, Cairo Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Ahmed MM Gebreel, MSc
• Email: agebreel@hotmail.com
• Phone: +201092576506

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• G-CSF for DOR in women undergoing IVF

  This trial tests whether G-CSF shots can improve IVF outcomes for women with diminished ovarian reserve.

  Recruiting Phase 4 Center for Human Reproduction · New York, New York · NCT07871825

• Predicting pregnancy outcomes after assisted reproduction using a machine-learning model

  A machine-learning model will be tested to see if early beta-hCG levels can predict live birth and identify pregnancies at risk after IVF or FET (with exploratory look at IUI).

  Recruiting at 2 sites BetaPlus Center for Reproductive Medicine · Rijeka and 1 other locations · NCT07855783

• Higher or lower starting FSH dose for good-prognosis IVF with PPOS

  This trial tests whether starting IVF stimulation with 225 IU or 300 IU of FSH improves oocyte and embryo outcomes in good-prognosis women using PPOS.

  Recruiting Vietnam Military Medical University · Ho Chi Minh City, Ho Chi Minh City · NCT07772375

• Environmental and lifestyle factors linked to ART success in infertility patients

  This study follows 5,000 infertile men and women to see how environmental exposures and lifestyle relate to the success of assisted reproductive technology.

  Recruiting The Third Xiangya Hospital of Central South University · Changsha, Hunan · NCT07641387

• Pentoxifylline to improve uterine lining and frozen embryo transfer outcomes

  This trial sees if giving pentoxifylline alongside standard estradiol helps women with good-quality day‑5 frozen embryos get a thicker uterine lining and better frozen embryo transfer success.

  Recruiting Phase 3 Beni-Suef University · Banī Suwayf, Beni Suweif Governorate · NCT07499817

• Tadalafil to increase uterine lining and improve frozen embryo transfer success

  This test sees if adding daily tadalafil to standard estrogen helps women with unexplained infertility using good-quality day‑5 frozen embryos get a thicker uterine lining and better transfer outcomes.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf, Beni Suweif Governorate · NCT07499804

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.